Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial.

Terence T Sio,Pamela J Atherton,Levi D Pederson, W Ken Zhen,Robert W Mutter,Yolanda I Garces,Daniel J Ma,James L Leenstra,Jean-Claude M Rwigema,Shaker Dakhil,James D Bearden,Sonja J van der Veen,Apar K Ganti,Steven E Schild,Robert C Miller

International Journal of Radiation Oncology*Biology*Physics（2019）

引用 16|浏览29

暂无评分

摘要

Although underpowered because of low accrual, our results suggest that there was a clinical signal for safety-and possibly beneficial by limited PRO measures-in concurrently administering lisinopril during thoracic CRT to mitigate or prevent RT-induced pulmonary distress. Our results showed that a definitive, larger-scale, randomized phase 3 trial is needed in the future.

查看译文

关键词

adverse effects,angiotensin-converting enzyme inhibitor,chemoradiation,lisinopril,lung cancer,patient-reported outcome,radiation pneumonitis,randomized,respiratory distress,safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要